<DOC>
	<DOCNO>NCT00752193</DOCNO>
	<brief_summary>The purpose study assess safety efficacy vaginally administer probiotic lactobacillus combination antibiotic therapy ( metronidazole ) woman microbiologically define bacterial vaginosis .</brief_summary>
	<brief_title>Safety Efficacy Vaginally Administered Probiotic Lactobacilli Delivery System .</brief_title>
	<detailed_description />
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<criteria>Untreated Bacterial Vaginosis ( BV ) ( asymptomatic symptomatic ) diagnose screen visit use Amsel criterion . Otherwise healthy ? premenopausal woman 1850 year age date screening . Regular menstrual cycle ( 2135 day ) amenorrheic least 3 month due use long act progestin continuous use oral contraceptive . Subject willing insert vaginal applicator . Subject willing ask question personal medical health sexual history Normal Pap smear collect screen visit ? If subject 's Visit 0 Pap smear result follow , person ineligible participation : ASCUS ( atypical squamous cell undetermined significance ) , AGC ( atypical glandular cell ) , ASCH ( atypical squamous cell , r/o high grade lesion ) , LSIL ( low grade squamous intraepithelial lesion ) , HSIL ( high grade squamous intraepithelial lesion ) , adenocarcinoma situ , adenocarcinoma , squamous cell carcinoma situ , squamous cell carcinoma inadequate sample Agree sexually abstinent 48 hour prior Visit 1 ( enrollment ) 48 hour application study product second time visit 2 . Agree abstain use intravaginal product ( i.e. , contraceptive cream , gel , foam , sponge , lubricant , douche , etc . ) throughout trial period . Agree use adequate method birth control duration study avoid pregnancy . Acceptable method include history tubal ligation , male partner vasectomy , steroidal contraceptive ( oral , patch , injectable implantable ) , IUD ( Paragard Mirena ) , condoms abstinence . Subject must access function refrigerator . Urogenital infection screen within 21 day prior screen . This include urinary tract infection , Trichomonas vaginalis , Neisseria gonorrhoeae , Chlamydia trachomatis Treponema pallidum . Subjects may rescreened least 21 day respective antibiotic antifungal therapy complete . History recurrent genital herpes . Diagnosis N. gonorrhoeae , C. trachomatis , T. pallidum T. vaginalis two occasion six month prior screen . Pregnancy within 2 month last pregnancy ( subject urine pregnancy test prior enrollment ) . Lactation . Vaginal systemic antibiotic antifungal therapy within 21 day Screening visit within 4 month Enrollment visit . Investigational drug use within 4 month 10 halflives drug , whichever longer , enrollment visit . Planned investigational drug use participate study . Menopause . IUD insertion removal within last 3 month . Pelvic surgery within last 3 month . Cervical cryotherapy cervical laser within last 3 month . Use NuvaRing® within 3 day screen visit course study . New longacting treatment ( e.g . depot formulation include medroxyprogesterone acetate ( DMPA ) form hormonal birth control ) . Subjects may enrol stable ( &gt; 3 month ) exist therapy determine Principal Investigator . Diabetes significant disease acute illness Investigator 's assessment could complicate evaluation . Known HIV infection positive HIV test screening . Immunosuppressive drug within 4 month . Previous participation L. crispatus clinical study . Colposcopic finding enrollment visit involve significant deep disruption epithelium . Known allergy component ( skim milk , … ) drug latex ( condom ) . Unavailable followup visit . History drug alcohol abuse . At enrollment , social medical condition , psychiatric illness , opinion Investigator , would preclude provision inform consent , make participation study unsafe , complicate interpretation study outcome data , otherwise interfere achieve study objective .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>